Notably, XPO1 inhibition also enhances the efficacy of adoptive cell therapies, as pre-treatment of tumor cells with selinexor sensitizes them to Chimeric Antigen Receptor (CAR)-T cells and bispecific antibody-mediated cytotoxicity, illustrating a dual role in directly modulating cancer cells and reshaping the immune landscape [53,54]. Here, XPO1 is linked to neoplasm.